Streetbeat News

Products Services

CMMB

Chemomab Therapeutics reported positive data from the secondary analysis of its Phase 2a liver fibrosis trial assessing CM-101, causing its shares to trade higher.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 11:20 am

EXAS

Exact Sciences has partnered with two renowned healthcare organizations to advance innovative cancer technologies and approaches. The collaboration aims to improve cancer detection, diagnosis, and treatment.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 11:19 am

RIVN

Rivian Automotive (NASDAQ:RIVN) plans to unveil its R2 SUV in early 2024, with a price range of $40,000 to $60,000, targeting a broader market segment. The R2 will maintain Rivian's adventure aesthetic while showcasing key trade-offs and investments.

Portfolio Pulse from Anan Ashraf

June 21, 2023 | 11:19 am

UBX

Unity Biotechnology announced the design of its Phase 2B ASPIRE clinical trial for UBX1325 (Foselutoclax) to be conducted head-to-head against Aflibercept in previously treated patients with active diabetic macular edema. The first patient is expected to be dosed in Q4 of 2023.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 11:17 am

PRTC

PureTech Health has initiated a Phase 2A proof-of-concept trial of LYT-300 (oral allopregnanolone) in healthy volunteers using a validated clinical model of anxiety. Results are expected by the end of 2023. A Phase 2A trial in patients with postpartum depression is planned to start in 2H 2023.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 11:15 am

XERS

Xeris Biopharma has announced the dosing of the first participant in a Phase 2 clinical study of its investigational subcutaneous levothyroxine (XP-8121) for patients with hypothyroidism.

Portfolio Pulse from Bill Haddad

June 21, 2023 | 11:11 am

PTCT

PTC Therapeutics shared interim data from the 12-week portion of the PIVOT-HD Phase 2 study of PTC 518 in Huntington's disease patients, showing dose-dependent lowering of huntingtin protein levels in peripheral blood cells.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 11:10 am

CMMB

Chemomab Therapeutics reports positive data from a secondary analysis of its Phase 2a liver fibrosis trial in NASH patients, showing that treatment with CM-101 improves additional biomarkers of fibrosis and inflammation, reinforcing and extending initial study results.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 11:08 am

QURE

uniQure announces interim data from Phase I/II trial of AMT-130 in Huntington's disease, showing preserved function and clinical benefits compared to the disease's natural history. The data supports continuing clinical development and pursuing regulatory interactions for late-stage development.

Portfolio Pulse from Bill Haddad

June 21, 2023 | 11:08 am

BLUE

bluebird bio announced that the FDA has granted priority review for its Biologics License Application (BLA) for lovotibeglogene autotemcel (lovo-cel) in patients with sickle cell disease aged 12 years and older with a history of vaso-occlusive events.

Portfolio Pulse from Bill Haddad

June 21, 2023 | 11:06 am